ABT vs RMD vs EW Stock Comparison

Abbott Laboratories, Resmed and Edwards Lifesciences Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$188.29B
P/E
40.1x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
1 win
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.55B
P/E
21.7x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
6 wins
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.69B
P/E
60.8x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
4 wins

Head to Head

11 decided of 12

Resmed leads on 6 of the 12 questions below (Resmed 6, Edwards Lifesciences 4, Abbott Laboratories 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTRMDEWLeader
Larger companyMarket capitalisation $188.29B $34.55B $61.69B ABT
Cheaper on earningsLower P/E, profitable companies only 40.1x 21.7x 60.8x RMD
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 18.5x 37.6x RMD
Faster revenue growthRevenue growth, trailing twelve months +10.0% +9.0% +13.4% EW
More profitableNet margin, trailing twelve months 9.7% 27.8% 15.2% RMD
Better return on capitalReturn on invested capital 5.7% 22.0% 8.7% RMD
Less leveragedLower net debt / EBITDA 2.5x -0.3x -2.5x EW
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -16.0% -5.0% +24.5% EW
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -1.2%/yr -1.6%/yr RMD
Less volatileAnnualised volatility, 1 year 28.5% 31.1% 25.5% EW
Higher overall scoreMean of the five percentile scores vs peers 56/100 80/100 77/100 RMD

Percentile Scorecard

ABTRMDEW

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTRMDEW
Valuation 74 #65 of 243 75 #62 of 243 61 #96 of 243
Growth 26 #168 of 228 60 #92 of 228 57 #99 of 228
Profitability 82 #41 of 222 99 #3 of 222 96 #10 of 222
Financial Health 33 #167 of 248 76 #61 of 248 87 #34 of 248
Shareholder Returns 65 #56 of 158 89 #18 of 158 84 #26 of 158
Overall 56 80 77
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • EW ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTRMDEWSPY
1 month +5.4%+1.7%+24.0% -2.0%
3 months -2.4%+6.7%+17.0% -2.8%
6 months +28.5%+18.6%+31.7% +2.0%
Year to date -13.4%-0.6%+25.7% +10.6%
1 year -16.0%-5.0%+24.5% +12.2%
3 years +11.8%+62.6%+62.9% +68.1%
3 years, per year +3.8%+17.6%+17.7% +18.9%
5 years -15.5%-6.0%-7.6% +61.4%
5 years, per year -3.3%-1.2%-1.6% +10.1%
10 years +170.4%+300.2%+253.3% +248.5%
10 years, per year +10.5%+14.9%+13.5% +13.3%

Risk

MeasureABTRMDEWSPY
Volatility, 1Y 28.5%31.1%25.5% 13.6%
Downside volatility, 1Y 27.8%33.9%24.7% 13.9%
Beta vs S&P 500, 1Y 0.070.510.58 1.00
Return / volatility, 1Y -0.56-0.160.96 0.90
Max drawdown, 5Y -41.6%-49.8%-54.3% -25.4%
From 52-week high -16.9%-13.2%0.0% -3.2%
52-week high $130.59$275.96$107.18 $779.14
52-week low $82.56$182.82$75.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTRMDEW
P/E now vs peer median 40.0xmedian 26.5x 21.5xmedian 26.5x 60.9xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 5.9xmedian 2.7x 9.2xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 15.8xmedian 18.4x 35.8xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 20.9xmedian 25.4x 43.3xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 5.7xmedian 2.5x 5.6xmedian 2.5x
PEG now vs peer median -13.92median 0.98 0.99median 0.98 -6.65median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTRMDEW
Revenue $48.23B $5.73B $6.67B
Gross profit $27.46B $3.50B $5.21B
Operating income $6.65B $1.89B $1.44B
Net income $4.70B $1.59B $1.02B
Free cash flow $6.76B $1.61B $1.42B
R&D $3.31B $393.82M $1.09B
EPS (diluted) $2.70 $11.11 $1.76
Cash & equivalents $4.05B $1.01B $3.11B
Total debt $31.16B $409.60M $598.80M
Shares (diluted) 1.74B 143.41M 577.60M
Enterprise value $162.16B $29.00B $44.89B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTRMDEW
P/E 40.0x 21.5x 60.9x
P/FCF 27.8x 20.9x 43.3x
P/Operating cash flow 21.2x 19.0x 35.9x
P/S 3.9x 5.9x 9.2x
P/B 3.6x 5.7x 5.6x
P/Tangible book 5.9x 6.1x 6.3x
EV/EBITDA 20.3x 15.8x 35.8x
EV/EBIT 32.3x 17.5x 40.0x
EV/Revenue 4.5x 5.8x 8.6x
EV/FCF 31.8x 20.6x 40.5x
EV/Operating cash flow 24.3x 18.7x 33.6x
PEG (3Y EPS CAGR) -13.92 0.99 -6.65

Growth

14 metrics
MetricABTRMDEW
Revenue growth (1Y) 10.0% 9.0% 13.4%
Revenue CAGR (3Y) 6.5% 9.4% 16.9%
Gross profit growth (1Y) 12.1% 11.0% 13.2%
Gross profit CAGR (3Y) 7.8% 13.2% 13.7%
Operating income growth (1Y) -13.8% 8.5% 1.1%
Operating income CAGR (3Y) 3.5% 18.2% 5.8%
Net income growth (1Y) -66.4% 10.8% -25.2%
Net income CAGR (3Y) -3.1% 20.7% -10.6%
EPS growth (1Y) -66.1% 13.5% -24.5%
EPS CAGR (3Y) -2.9% 21.8% -9.2%
Operating cash flow growth (1Y) -2.9% -6.0% 68.9%
Operating cash flow CAGR (3Y) 10.6% 23.7% 18.1%
Free cash flow growth (1Y) -2.3% -9.0% 77.1%
Free cash flow CAGR (3Y) 14.6% 25.5% 20.8%

Profitability

14 metrics
MetricABTRMDEW
Gross margin 56.9% 61.1% 78.0%
EBITDA margin 21.9% 36.4% 24.2%
Operating margin 13.8% 33.0% 21.6%
Pretax margin 13.6% 35.1% 21.5%
Net margin 9.7% 27.8% 15.2%
FCF margin 14.0% 28.1% 21.3%
Operating cash flow margin 18.4% 30.9% 25.7%
Return on equity 9.1% 25.4% 9.4%
Return on assets 4.3% 18.5% 7.2%
Return on invested capital 5.7% 22.0% 8.7%
Return on capital employed 7.2% 26.1% 11.6%
Asset turnover 0.4x 0.7x 0.5x
Cash conversion (OCF / net income) 1.9x 1.1x 1.7x
Stock comp / revenue 1.5% 2.0% 2.6%

Financial Health

11 metrics
MetricABTRMDEW
Debt / assets 28.8% 5.0% 4.2%
Debt / equity 0.6x 0.1x 0.1x
Net debt / EBITDA 2.5x -0.3x -2.5x
Debt / FCF 4.6x 0.3x 0.4x
Liabilities / assets 52.3% 27.6% 22.5%
Equity / assets 47.7% 72.4% 77.5%
Interest coverage 6.7x 81.1x –
Current ratio 1.5x 2.6x 4.6x
Quick ratio 0.8x 1.5x 3.5x
Cash ratio 0.3x 0.8x 2.9x
Altman Z-score 3.36 12.00 14.42

Shareholder Returns

7 metrics
MetricABTRMDEW
Dividend yield 2.3% 1.1% –
Net buyback yield 0.7% 4.2% 0.9%
Shareholder yield 3.0% 5.3% 0.9%
Payout ratio (earnings) 92.0% – –
Payout ratio (FCF) 64.0% – –
Dividend growth (1Y) 6.9% – –
Dividend CAGR (3Y) 7.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTRMDEW
Forward P/E 19.1xFY2026 18.5xFY2027 37.6xFY2026
EPS, next fiscal year $5.69FY2026 $12.92FY2027 $2.85FY2026
EPS growth, next FY +10.5%FY2026 +15.7%FY2027 +11.3%FY2026
EPS growth, the year after +10.2% +8.9% +12.6%
Revenue, next fiscal year $52.99BFY2026 $5.99BFY2027 $7.28BFY2026
Revenue growth, next FY +19.5%FY2026 +6.0%FY2027 +19.9%FY2026
Revenue growth, the year after -2.3% -3.8% -2.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTRMDEW
Held by institutions 79.2% 68.7% 90.6%
Institutions holding 2,983 889 1,326
Change in shares held, QoQ +0.3% +3.2% +20.4%
Institutions buying 1,261 404 641
Institutions selling 1,379 360 456
Buyers to sellers 0.91 1.12 1.41

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTRMDEW
ABT 1.00 0.41 0.32
RMD 0.41 1.00 0.35
EW 0.32 0.35 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, RMD and EW?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $188.29B, Resmed (RMD) $34.55B, Edwards Lifesciences (EW) $61.69B.

Which stock is cheaper, ABT, RMD and EW?

Resmed (RMD) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 40.1x, Resmed (RMD) 21.7x, Edwards Lifesciences (EW) 60.8x). On next year's consensus earnings, Resmed (RMD) is cheapest (Abbott Laboratories (ABT) 19.1x, Resmed (RMD) 18.5x, Edwards Lifesciences (EW) 37.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Resmed (RMD) +9.0%, Edwards Lifesciences (EW) +13.4%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Resmed (RMD) 27.8%, Edwards Lifesciences (EW) 15.2%). On return on invested capital, Resmed (RMD) leads (Abbott Laboratories (ABT) 5.7%, Resmed (RMD) 22.0%, Edwards Lifesciences (EW) 8.7%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Abbott Laboratories (ABT) -16.0%, Resmed (RMD) -5.0%, Edwards Lifesciences (EW) +24.5%. Over five years, Resmed (RMD) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Resmed (RMD) -1.2%/yr, Edwards Lifesciences (EW) -1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Abbott Laboratories (ABT) 0.02%, Resmed (RMD) 0.00%, Edwards Lifesciences (EW) 0.00%. Resmed (RMD) and Edwards Lifesciences (EW) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Resmed (RMD) 31.1%, Edwards Lifesciences (EW) 25.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, RMD and EW?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Resmed (RMD) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.